undamentalytics Newsletter

Gorlin Steve: insider trades

Director at 3 companies we cover. 6 open-market purchases and 22 sales not made under a pre-set plan, reported from March 5, 2012 to December 6, 2023.

Would copying Gorlin Steve’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 6 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on October 15, 2020 into $5,785 by November 2, 2026, −8.7% a year. The copy held shares only 19% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $16,606, +8.8% a year (the S&P 500 held throughout made $23,603, +15.3% a year). Beta against the index was 0.25. Twelve months after each report, the average purchase was −78.3% against the S&P 500 (median −72.9%), and 0% beat it. Measured from the trade date, the insider’s own timing, the average was −63.5%. After their sales, the shares moved −53.4% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 2020202120222023202420252026 $23.6k$16.6k$5.8k
Copying Gorlin SteveS&P 500, same days investedS&P 500, held throughout $10,000 copying Gorlin Steve’s open-market purchases from October 15, 2020, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−8.7%
S&P 500, same days invested
+8.8% (held throughout +15.3%)
Time in shares
19%
Sharpe ratio (S&P 500)
0.04 (0.74)
Biggest drop (S&P 500)
−89% (−25%)
Market sensitivity (beta)
0.25
Purchases copied
6

Trade by trade

Gorlin Steve: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 6 +200.8% +259.0% 100% 1 — — Not enough years
Purchases, 6 months after the report 6 +26.3% +13.8% 67% 1 — — Not enough years
Purchases, 12 months after the report 6 −78.3% −72.9% 0% 1 — — Not enough years
Purchases, 12 months after the trade 6 −63.5% −63.8% 0% 1 — — Not enough years
Sales, 3 months after the report 5 −15.6% −20.9% 80% 3 — — Not enough years
Sales, 12 months after the report 5 −53.4% −69.1% 100% 3 — — Not enough years
Sales, 12 months after the trade 4 −64.6% −69.0% 100% 3 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Immunitybio, Inc. IBRX —014August 25, 2015December 3, 2018
Biovie Inc. BIVI —62October 14, 2020December 6, 2023
Mimedx Group, Inc. MDXG —06March 5, 2012May 30, 2013

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
December 6, 2023December 1, 2023 BIVI Sale $127,899 not yetnot yetnot yet
September 7, 2023September 5, 2023 BIVI Sale $26,108 not yetnot yetnot yet
December 15, 2020November 3, 2020 BIVI Purchase $19,318 +60.9%−90.2%−55.6%
December 15, 2020October 30, 2020 BIVI Purchase $20,483 +60.9%−90.2%−60.1%
October 22, 2020October 21, 2020 BIVI Purchase $45,950 +304.8%−73.0%−71.8%
October 19, 2020October 15, 2020 BIVI Purchase $152,517 +258.0%−71.1%−72.8%
October 14, 2020October 7, 2020 BIVI Purchase $44,444 +259.9%−72.8%−67.5%
October 14, 2020September 22, 2020 BIVI Purchase $150,000 +259.9%−72.8%−53.5%
December 3, 2018November 29, 2018 IBRX Sale $228,276 not yetnot yetnot yet
November 29, 2018November 27, 2018 IBRX Sale $262,999 not yetnot yetnot yet
November 26, 2018November 21, 2018 IBRX Sale $64,975 not yetnot yetnot yet
November 14, 2018November 12, 2018 IBRX Sale $450,457 not yetnot yetnot yet
August 27, 2018August 23, 2018 IBRX Sale $153,651 not yetnot yetnot yet
June 7, 2018June 5, 2018 IBRX Sale $296,477 not yetnot yetnot yet
June 1, 2018May 30, 2018 IBRX Sale $10,569 not yetnot yetnot yet
May 29, 2018May 24, 2018 IBRX Sale $23,669 not yetnot yetnot yet
May 23, 2018May 21, 2018 IBRX Sale $54,233 not yetnot yetnot yet
May 22, 2018May 18, 2018 IBRX Sale $63,405 not yetnot yetnot yet
May 17, 2018May 15, 2018 IBRX Sale $331,271 not yetnot yetnot yet
September 13, 2017September 13, 2017 IBRX Sale $234,852 −20.9%−69.1%−69.4%
September 12, 2017September 8, 2017 IBRX Sale $627,486 −22.4%−69.4%−68.5%
August 25, 2015August 21, 2015 IBRX Sale $10,350,000 −26.7%−75.1%−79.8%
May 30, 2013May 16, 2013 MDXG Sale $193,800 −11.5%−44.7%−40.6%
April 19, 2013April 17, 2013 MDXG Sale $99,800 +3.7%−8.7%not yet
November 6, 2012November 2, 2012 MDXG Sale $288,900 not yetnot yetnot yet
September 12, 2012September 10, 2012 MDXG Sale $195,210 not yetnot yetnot yet
July 3, 2012June 29, 2012 MDXG Sale $1,550,000 not yetnot yetnot yet
March 5, 2012March 2, 2012 MDXG Sale $250,000 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Gorlin Steve traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.